ClearB Therapeutics

Pre-clinical

Newton, United StatesFounded 2016clearbtherapeutics.com

ClearB Therapeutics is focused on addressing the substantial unmet need in chronic hepatitis B by developing immune-redirecting therapeutic vaccines. Its lead candidate, CLB-4000, is a bivalent subunit vaccine comprised of engineered HBsAg variants designed to over-represent clearance profile epitopes, adjuvanted with a novel saponin. The company has initiated a Phase 1b clinical trial in non-cirrhotic adults with CHB and is positioned to contribute to evolving treatment regimens aimed at functional cure.

Founded

2016

Focus

BiologicsVaccines

AI Company Overview

Technology Platform

A therapeutic vaccine platform featuring engineered HBsAg variants designed to over-represent clearance-associated epitopes, combined with a novel semi-synthetic saponin adjuvant (TQL-1055), aimed at redirecting the immune system to achieve functional cure in chronic hepatitis B.

Opportunities

The primary opportunity is addressing the massive unmet need for a functional cure in over 250 million people with chronic hepatitis B worldwide.

Success with CLB-4000 could position ClearB as a key player in combination treatment regimens, potentially leading to partnerships with large pharmaceutical companies or an acquisition.

The therapeutic vaccine approach, if successful, may also have applicability in other chronic viral infections or oncology.

Risk Factors

Key risks include the high failure rate of early-stage clinical trials, the scientific challenge of breaking immune tolerance in CHB, intense competition from other modalities (RNAi, CAMs), and dependence on raising additional private capital to fund development.

The company's future hinges on the upcoming Phase 1b data readouts.

Competitive Landscape

ClearB competes in a crowded HBV functional cure landscape against companies developing RNAi therapies (Arrowhead, Vir/Alnylam), other therapeutic vaccines (VBI Vaccines, Altimmune), and capsid inhibitors. Its differentiation lies in its engineered antigen design based on functional cure patient epitopes and its novel adjuvant system, but it must demonstrate superior clinical proof-of-concept to stand out.